Premium
Heat shock protein‐60 expression was significantly correlated with the prognosis of lung adenocarcinoma
Author(s) -
Xu Xin,
Wang Wei,
Shao Wenlong,
Yin Weiqiang,
Chen Hanzhang,
Qiu Yuan,
Mo Mingcong,
Zhao Jin,
Deng Qiuhua,
He Jianxing
Publication year - 2011
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21992
Subject(s) - adenocarcinoma , medicine , immunohistochemistry , stage (stratigraphy) , pathological , lung , oncology , hsp60 , heat shock protein , biomarker , multivariate analysis , pathology , lung cancer , gastroenterology , cancer , hsp70 , biology , gene , paleontology , biochemistry
Background The purpose of this study was to investigate the role of heat shock protein 60 (HSP60) in the clinical pathology of lung adenocarcinoma, and to explore whether the expression of HSP60 can act as an independent predictor for tumor relapse and prognosis after radical resection of lung adenocarcinoma. Methods Paraffin sections of lung adenocarcinoma tumor tissues were collected from 103 patients. Using immunohistochemistry, the expression levels of HSP60 in lung adenocarcinoma were detected. The correlations between HSP60 expression and clinicopathological parameters as well as prognosis were statistically analyzed. Results Of the 103 specimens, 70 cases (68.0%) showed a strongly positive expression of HSP60, five cases (4.8%) showed a negative expression, and 28 cases (27.2%) showed a weakly positive expression. The level of HSP60 expression was significantly correlated with TNM stage of the tumor ( P = 0.015), and Eastern Cooperative Oncology Group (ECOG) performance status( P = 0.027). Multivariate statistical analysis showed that patient age, pathological T stage, N stage, and HSP60 expression were independent prognostic influence on disease‐free survival ( P = 0.008, 0.011, 0.010, and <0.001, respectively). Conclusions HSP60 may be a good biomarker to be applied in clinic to predict the prognosis of patients with lung adenocarcinoma J. Surg. Oncol. 2011; 104:598–603. © 2011 Wiley Periodicals, Inc.